Browse

Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer

DC Field Value Language
dc.contributor.authorSun, Jong-Mu-
dc.contributor.authorLee, Keun-Wook-
dc.contributor.authorKim, Jee Hyun-
dc.contributor.authorKim, Yu Jung-
dc.contributor.authorLee, Jae-Ho-
dc.contributor.authorLee, Jong Seok-
dc.contributor.authorLee, Choon-Taek-
dc.contributor.authorYoon, Ho Il-
dc.date.accessioned2012-06-25T08:55:16Z-
dc.date.available2012-06-25T08:55:16Z-
dc.date.issued2009-01-
dc.identifier.citationJAPANESE JOURNAL OF CLINICAL ONCOLOGY; Vol.39 1; 27-32ko_KR
dc.identifier.issn0368-2811-
dc.identifier.urihttp://hdl.handle.net/10371/77403-
dc.description.abstractPemetrexed has been approved for second-line treatment in non-small cell lung cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet been generally accepted. We attempted to validate third-line pemetrexed therapy and evaluate predictive factors for pemetrexed therapy for NSCLC. Medical records of NSCLC patients who received pemetrexed therapy that progressed after systemic therapy were reviewed retrospectively. We stratified patients according to clinicopathologic characteristics to find predictive factors for pemetrexed therapy. A total of 100 patients were eligible for analysis, and overall progression-free survival (PFS) was 3.03 months. The objective response rate was 12%, and the toxicity profile was favorable. Pemetrexed was used as a second-line treatment in 30% of patients, and as third- or further-line treatment in 70%. Comparing the efficacy of pemetrexed in these two settings (second-line versus third- or further-line), there was no significant difference in terms of PFS (3.07 versus 2.83 months, P = 0.86). When we evaluated predictive factors by multivariate analysis, performance status significantly influenced PFS. Pemetrexed is a suitable third-line treatment option with good efficacy and tolerable toxicity profile for NSCLC.ko_KR
dc.language.isoenko_KR
dc.publisherOXFORD UNIV PRESSko_KR
dc.subjectnon-small cell lung cancerko_KR
dc.subjectsecond-lineko_KR
dc.subjectthird-lineko_KR
dc.subjectpemetrexedko_KR
dc.titleEfficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancerko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor선종무-
dc.contributor.AlternativeAuthor이근욱-
dc.contributor.AlternativeAuthor김지현-
dc.contributor.AlternativeAuthor김유정-
dc.contributor.AlternativeAuthor윤호일-
dc.contributor.AlternativeAuthor이재호-
dc.contributor.AlternativeAuthor이춘택-
dc.contributor.AlternativeAuthor이종석-
dc.identifier.doi10.1093/jjco/hyn118-
dc.citation.journaltitleJAPANESE JOURNAL OF CLINICAL ONCOLOGY-
dc.description.citedreferenceScagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375-
dc.description.citedreferenceKulkarni PM, 2008, CRIT REV ONCOL HEMAT, V67, P64, DOI 10.1016/j.critrevonc.2008.01.011-
dc.description.citedreferenceOhe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1168/1078-0432.CCR-07-5143-
dc.description.citedreferenceBearz A, 2008, LUNG CANCER, V60, P240, DOI 10.1016/j.lungcan.2007.10.008-
dc.description.citedreferencede Marinisa F, 2008, ONCOLOGIST, V13, P14, DOI 10.1634/theoncologist.13-S1-14-
dc.description.citedreferenceCIULEANU TE, 2008, P AM SOC CLIN ONCOL, V26-
dc.description.citedreferencePujol JL, 2007, J THORAC ONCOL, V2, P397-
dc.description.citedreferenceWeiss GJ, 2007, ANN ONCOL, V18, P453, DOI 10.1093/annonc/mdl454-
dc.description.citedreferenceWeiss GJ, 2006, J CLIN ONCOL, V24, P4405, DOI 10.1200/JCO.2006.06.7835-
dc.description.citedreferenceMurillo JR, 2006, ONCOLOGIST, V11, P1095, DOI 10.1634/theoncologist.11-10-1095-
dc.description.citedreferenceShepherd FA, 2005, NEW ENGL J MED, V353, P123-
dc.description.citedreferenceHanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163-
dc.description.citedreferenceTrotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S01053-4296(03)00031-6-
dc.description.citedreferenceMassarelli E, 2003, LUNG CANCER-J IASLC, V39, P55-
dc.description.citedreferenceBreathnach OS, 2001, J CLIN ONCOL, V19, P1734-
dc.description.citedreferenceFossella FV, 2000, J CLIN ONCOL, V18, P2354-
dc.description.citedreferenceShepherd FA, 2000, J CLIN ONCOL, V18, P2095-
dc.description.citedreferenceTherasse P, 2000, J NATL CANCER I, V92, P205-
dc.description.tc13-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse